ES2146228T3 - Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos. - Google Patents

Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.

Info

Publication number
ES2146228T3
ES2146228T3 ES93906193T ES93906193T ES2146228T3 ES 2146228 T3 ES2146228 T3 ES 2146228T3 ES 93906193 T ES93906193 T ES 93906193T ES 93906193 T ES93906193 T ES 93906193T ES 2146228 T3 ES2146228 T3 ES 2146228T3
Authority
ES
Spain
Prior art keywords
epiandrosterone
dehydro
analogs
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906193T
Other languages
English (en)
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Application granted granted Critical
Publication of ES2146228T3 publication Critical patent/ES2146228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE PRESENTA UN METODO PARA COMBATIR EL CANCER DE UN SUJETO QUE CONSISTE EN ADMINISTRAR A DICHO SUJETO DESHIDROEPIANDROSTERONA (DHEA) O UN ANALOGO DE LA MISMA EN UNA CANTIDAD EFECTIVA COMO PARA COMBATIR EL CANCER SEGUN EL CUAL LOS COLAPSOS INDUCIDOS POR LA DHEA O EL ANALOGO DE LA MISMA SE COMBATEN ADMINISTRANDO AL SUJETO UNA UBIQUINONA, EN UNA CANTIDAD EFECTIVA COMO PARA COMBATIR EL COLAPSO INDUCIDO POR LA DHEA O EL ANALOGO DE LA MISMA. UN ANALOGO DE LA DHEA PREFERENTE PARA LLEVAR A CABO EL METODO DE LA INVENCION ES LA 16 ALFA-FLUOREPIANDROSTERONA Y UNA UBIQUINONA PREFERENTE PARA LLEVAR A CABO EL METODO DE LA INVENCION ES LA COENZIMA Q10.
ES93906193T 1992-02-24 1993-02-23 Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos. Expired - Lifetime ES2146228T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84051092A 1992-02-24 1992-02-24

Publications (1)

Publication Number Publication Date
ES2146228T3 true ES2146228T3 (es) 2000-08-01

Family

ID=25282563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906193T Expired - Lifetime ES2146228T3 (es) 1992-02-24 1993-02-23 Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.

Country Status (9)

Country Link
US (1) US5527789A (es)
EP (1) EP0627921B1 (es)
JP (1) JPH07504198A (es)
AT (1) ATE193447T1 (es)
AU (1) AU676470B2 (es)
CA (1) CA2117532C (es)
DE (1) DE69328771T2 (es)
ES (1) ES2146228T3 (es)
WO (1) WO1993016704A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US7893044B2 (en) 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
NZ536787A (en) 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
EP1553954A4 (en) * 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
JP6058263B2 (ja) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー 癌細胞においてアポトーシスを誘導する方法および使用
US20140024022A1 (en) * 2009-02-09 2014-01-23 Nihon Kohden Corporation Cell treatment solution and method of preparing stained cell suspension for a measurement of nuclear dna by flow cytometry
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
BR112012022916B1 (pt) 2010-03-12 2021-11-09 Berg Llc Formulações intravenosas de coenzima q10 (coq10), bem como método de preparação e uso da mesma
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
US20140239525A1 (en) 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
US20130064815A1 (en) * 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
TW201831436A (zh) * 2017-02-24 2018-09-01 郭盈妤 分離自牛樟芝的化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5001119A (en) * 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
DE69033541D1 (de) * 1989-09-25 2000-06-15 Univ Utah Res Found Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
IE900306A1 (en) * 1990-01-29 1991-07-31 Elan Corp Agent for use in the prevention, control or reversal of¹hypertension

Also Published As

Publication number Publication date
ATE193447T1 (de) 2000-06-15
JPH07504198A (ja) 1995-05-11
DE69328771D1 (de) 2000-07-06
WO1993016704A1 (en) 1993-09-02
CA2117532A1 (en) 1993-09-02
AU3731793A (en) 1993-09-13
US5527789A (en) 1996-06-18
DE69328771T2 (de) 2000-12-07
EP0627921B1 (en) 2000-05-31
EP0627921A1 (en) 1994-12-14
AU676470B2 (en) 1997-03-13
EP0627921A4 (en) 1995-03-01
CA2117532C (en) 2001-04-10

Similar Documents

Publication Publication Date Title
EP0627921A4 (en) METHOD FOR INHIBITING CARCINOGENESIS BY TREATMENT WITH DEHYDROEPIANDROSTERONE AND ITS ANALOGS.
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
ES2058799T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
ES2045110T3 (es) Mejoras en o relacionadas con antagonistas de leucotrienos.
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
ES2071989T3 (es) Analogos de oligonucleotidos.
ES2184929T3 (es) Mezclas de organo-polisulfanos y procedimiento para la preparacion de mezclas de caucho que los contienen.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ES2081005T3 (es) 9-amino-7-sustituido-6-demetil-6-deoxitetraciclinas.
ES2114620T3 (es) Composiciones antitumorales que contienen derivados del taxano.
ES2059571T3 (es) Fumagilina como agente angiostatico.
ES2089301T3 (es) Formulaciones analogas de lh-rh.
ES2168254T3 (es) Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
ES2173978T3 (es) Utilizacion de un alcohol graso insaturado.
MX9305934A (es) Nuevo modificador de resistencia a drogas multiples.
ES507394A0 (es) Mejoras en el objeto de la patente de invencion n.487.721 por procedimiento de preparacion de nuevos derivados del nortropano.
ES2033426T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
ES2032016T3 (es) Un procedimiento para la produccion de las 13, 14-ceto-pgfs.
ES2140436T3 (es) Esteroides de 17-espirometileno.
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
ES2192668T3 (es) Compuestos biciclicos-aromaticos.
ES2125426T3 (es) Composicion a base de esteres de c12 a c20 y utilizacion en el desmaquillaje.
AR002909A1 (es) Composicion fungicida y procedimiento para combatir hongos fitopatogenos.
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 627921

Country of ref document: ES